摘要
肺癌是世界上最大的恶性肿瘤之一,其中非小细胞肺癌(NSCLC)占肺癌的80%.肺癌发病快,死亡率高,严重威胁人类健康.普拉替尼(Pralsetinib)是一种选择性转染重排(rearranged during transfection,RET)抑制剂,用于转移性RET融合阳性NSCLC患者的治疗.本文就Pralsetinib的合成、药效学、药代动力学以及毒副作用等几个方面对Pralsetinib进行介绍.
Lung cancer is one of the largest malignant tumors in the world,with non-small-cell lung cancer(NSCLC)accounting for 80%of lung cancer.Lung cancer has a high incidence and a high mortality rate,which poses a serious threat to human health.Pralsetinib is a selective rearranged during transfection(RET)inhibitor used in the treatment of metastatic RET fusion-positive NSCLC patients.This paper introduces Pralsetinib through the synthesis,pharmacological,pharmacokinetics and toxic side effects of Pralsetinib.
作者
陈烨
王小涵
王铭
代洪爽
崔永生
CHEN Ye;WANG Xiao-han;WANG Ming;DAI Hong-shuang;CUI Yong-sheng(College of Pharmacy,Liaoning University,Shenyang 110036,China;Business College,Shenyang City University,Shenyang 110112,China)
出处
《辽宁大学学报（自然科学版）》
CAS
2022年第1期61-68,共8页
Journal of Liaoning University：Natural Sciences Edition
作者简介
陈烨(1965-),男,辽宁沈阳人,教授,研究方向:创新药物研发;通讯作者:崔永生,E-mail:yhl3655@126.com.
